Eli Lilly Yönetim

Yönetim kriter kontrolleri 2/4

Eli Lilly CEO'su Dave Ricks, Jan2017 tarihinde atandı, in görev süresi 7.83 yıldır. in toplam yıllık tazminatı $ 26.57M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.1% maaş ve 93.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.067% ine doğrudan sahiptir ve bu hisseler CLP 447.32B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.2 yıl ve 8.4 yıldır.

Anahtar bilgiler

Dave Ricks

İcra Kurulu Başkanı

US$26.6m

Toplam tazminat

CEO maaş yüzdesi	6.1%
CEO görev süresi	7.8yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	6.2yrs
Yönetim Kurulu ortalama görev süresi	8.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dave Ricks'un ücretlendirmesi Eli Lilly'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

Tazminat ve Piyasa: Dave 'nin toplam tazminatı ($USD 26.57M ), CL pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.71M ).

Tazminat ve Kazançlar: Dave 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Dave Ricks (56 yo)

7.8yrs

Görev süresi

US$26,565,732

Tazminat

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% CLP 447.3b
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.4yrs	US$11.85m	0.021% CLP 143.0b
Anat Hakim	Executive VP	4.8yrs	US$7.01m	0.0034% CLP 22.5b
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% CLP 15.2b
Lucas Montarce	Executive VP & CFO	less than a year	Veri yok	0.0012% CLP 8.2b
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	12yrs	Veri yok	0.00080% CLP 5.3b
Diogo Rau	EVP & Chief Information and Digital Officer	3.5yrs	US$5.10m	0.0012% CLP 8.2b
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	3.4yrs	Veri yok	0.00088% CLP 5.9b
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.9yrs	Veri yok	0.00093% CLP 6.2b
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.8yrs	US$5.38m	Veri yok
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.3yrs	Veri yok	Veri yok
Anne White	EVP & President of Lilly Neuroscience	6.2yrs	Veri yok	0.0073% CLP 48.5b

6.2yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: LLYCL 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% CLP 447.3b
Gabrielle Greene-Sulzberger	Independent Director	3.8yrs	US$335.50k	0.00028% CLP 1.9b
Sidney Taurel	Chairman Emeritus	15.8yrs	US$13.06m	Veri yok
Jon Erik Fyrwald	Independent Director	19yrs	US$344.88k	0.000010% CLP 66.6m
Ralph Alvarez	Independent Director	15.6yrs	US$336.00k	0.000080% CLP 532.4m
William Kaelin	Independent Director	12.4yrs	US$349.15k	0.0024% CLP 15.8b
Mary Hedley	Independent Director	2.5yrs	US$319.00k	0.000040% CLP 266.2m
Juan Luciano	Lead Independent Director	8.8yrs	US$373.00k	0.0018% CLP 11.9b
Katherine Baicker	Independent Director	12.9yrs	US$336.00k	0.0026% CLP 17.1b
Jamere Jackson	Independent Director	8.1yrs	US$345.00k	0.0010% CLP 6.8b
Karen Walker	Independent Director	5.9yrs	US$359.00k	0.00069% CLP 4.6b
Kimberly Johnson	Independent Director	3.8yrs	US$316.00k	0.00033% CLP 2.2b

8.4yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LLYCL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.4 yıldır).

Eli Lilly Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Insufficient new directors

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Announces Positive Phase 2 Results for muvalaplin

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.064 loss in 3Q 2023)

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Second quarter 2024 earnings released: EPS: US$3.29 (vs US$1.96 in 2Q 2023)

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Insufficient new directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş